Valuation: EyePoint, Inc.

Market Cap 295M 260M 246M 223M 419M 28.29B 423M 2.95B 1.14B 14.45B 1.11B 1.08B 46.49B P/E 2026 *
-0.93x
P/E 2027 * -1.31x
Enterprise Value -27.95M -24.66M -23.34M -21.16M -39.68M -2.68B -40.07M -280M -108M -1.37B -105M -103M -4.41B EV / Sales 2026 *
-16.3x
EV / Sales 2027 * -1.09x
Free-Float
96.47%
Yield 2026 *
-
Yield 2027 * -
1 day+3.32%
1 week-15.97%
Current month-24.00%
1 month-23.66%
3 months-75.76%
6 months-72.64%
Current year-81.28%
1 week 3.26
Extreme 3.265
3.72
1 month 3.26
Extreme 3.265
4.92
Current year 3.26
Extreme 3.265
18.87
1 year 3.26
Extreme 3.265
19.11
3 years 3.26
Extreme 3.265
30.99
5 years 2.19
Extreme 2.19
30.99
10 years 2.19
Extreme 2.19
39.4
Manager TitleAgeSince
Chief Executive Officer 67 10/07/2023
Director of Finance/CFO 61 14/11/2019
Chief Tech/Sci/R&D Officer 43 04/03/2024
Director TitleAgeSince
Director/Board Member 67 10/07/2023
Chairman 77 10/09/2018
Director/Board Member 73 25/10/2018
Date Insider Type Main position Quantity % Market Cap. Importance
8/20/26 A Others

Chief Financial Officer

-139,906 0.1669%
8/18/26 A Buy

Director

10,600 0.0126%
7/10/26 A Exercice

Chief Executive Officer

41,393 0.0494%
Change 5-day change 1-year change 3-year change Capi.($)
+3.32%-15.97%-75.66%-57.20% 285M
-0.01%+1.24%+63.06%+120.55% 1,056B
-1.61%-0.60%+47.32%+71.79% 655B
-1.12%-0.72%+17.98%+76.63% 471B
-1.72%-4.06%+36.39%+39.47% 342B
-0.40%+3.83%+22.08%+28.82% 277B
-0.51%-1.93%+12.09%+11.94% 257B
+1.32%+3.27%+54.63%+57.63% 226B
-0.61%-0.91%+34.33%+101.87% 189B
-0.24%-2.76%-28.41%-60.92% 170B
Average +0.16%-1.51%+18.38%+39.06% 364.32B
Weighted average by Cap. -0.05%+0.41%+38.90%+70.51%

Financials

2026 *2027 *
Net sales 1.72M 1.52M 1.43M 1.3M 2.44M 165M 2.46M 17.21M 6.63M 84.19M 6.45M 6.31M 271M 17.93M 15.82M 14.97M 13.57M 25.45M 1.72B 25.7M 180M 69.2M 878M 67.31M 65.85M 2.83B
Net income -344M -304M -287M -261M -489M -33.02B -493M -3.45B -1.33B -16.86B -1.29B -1.26B -54.26B -287M -253M -239M -217M -407M -27.5B -411M -2.87B -1.11B -14.04B -1.08B -1.05B -45.18B
Net Debt -323M -285M -270M -244M -458M -30.97B -463M -3.23B -1.25B -15.82B -1.21B -1.19B -50.9B -314M -278M -263M -238M -446M -30.17B -451M -3.15B -1.21B -15.41B -1.18B -1.16B -49.58B
Logo EyePoint, Inc.
EyePoint, Inc., formerly EyePoint Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU, is an investigational-sustained delivery treatment for serious retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor, with bioerodible Durasert E technology. Vorolanib features a novel multi-mechanism of action as it targets both vascular endothelial growth factor (VEGF)-mediated vascular permeability and IL-6 mediated inflammation through inhibition of all VEGF receptors and pro-inflammatory IL-6/JAK1 signaling. DURAVYU is in Phase III pivotal trials for wet age-related macular degeneration. DURAVYU is also being advanced for the treatment of diabetic macular edema (DME) with the first patient dosing in Phase III trials.
Employees
-
Date Price Change Volume
29/09/26 $3.420 +3.32% 2,542,246
28/09/26 $3.310 -8.56% 3,296,631
25/09/26 $3.620 -0.82% 2,250,781
24/09/26 $3.650 -1.88% 2,301,753
23/09/26 $3.720 -8.60% 2,022,398
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
13
Last Close Price
3.420USD
Average target price
25.91USD
Spread / Average Target
+657.58%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. EYPT Stock